The purpose of this study is to determine the response and the duration of it in patients affected by ALK+ lymphoma that are resistant or refractory to standard cytotoxic treatment that will be treated with crizotinib.
Name: crizotinib
Type: Drugcrizotinib
Single Group Assignment
There is one SNP
Although crizotinib shows activity, relapses occur typically within 5 months after starting treatment and were supported by mutations like I1171N. --- I1171N ---